Jessica Schmitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica Schmitt has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Joycelyn Atchison
Department of Pediatrics University of Alabama at Birmingham Heersink School of Medicine Birmingham Alabama USA
2 shared publications Mary Lauren Scott
University of Alabama at Birmingham Department of Pediatrics, Birmingham, Alabama, USA
2 shared publications- Meryl C. Nath
University of Alabama at Birmingham Heersink School of Medicine Birmingham Alabama USA
2 shared publications A. G. Barajas
University of Alabama at Birmingham Marnix E. Heersink School of Medicine Birmingham Alabama USA
1 shared publicationA. K. M. Falzur Rahman
Department of Biostatistics , University of Alabama at Birmingham , Birmingham, AL , USA
1 shared publicationAkm. Fazlur Rahman
Department of Biostatistics University of Alabama at Birmingham Birmingham AL USA
1 shared publication
Latest Publications
- Open Access
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1568133
Patient outcomes after attending pre-pump education class: disparities in initiation and glycemic outcomes
Background: At Children’s of Alabama, all patients with insulin dependent diabetes are considered for continuous subcutaneous insulin infusion therapy (CSII, also known as insulin pump). In some cases, eligibility depends on insurance requirements, including six months of MDI therapy, CSII education, and a six-week glucose log with four daily readings.Objective: Evaluate factors influencing CSII initiation after “Prepump class” and assess glycemic changes in CSII starters.Methods: A retrospective review of pre-pump class attendees from January 2022 to July 2023 was completed. Patients who initiated a CSII prior to January 2024 were identified as “CSII-starters,” and those who remained in multiple daily injections were identified as “MDI-retainers”. Demographic and medical data were compared between these groups. For CSII-starters, type of system and use of automatic insulin delivery (AID) was evaluated. Glycemic outcomes were assessed in those with type 1 diabetes (T1D) with continuous glucose monitor data. A sub-analysis was done for those outside the honeymoon period. Outcomes of AID systems and users of non-AID systems were compared.Results: Of 283 pediatric patients who attended pre-pump class, 187 (66%) started CSII, with a median initiation time of 108 days (interquartile range 76–154). CSII-starters and MDI-retainers differed by race (p=0.0385) and insurance (p=0.0001), but not by sex, language, or age at diagnosis. Initiators were younger (p=0.0150), had shorter diabetes duration (p=0.0001), lower HbA1c (p=0.0020), and higher CGM use (p<0.0001). Among starters, 70% chose tubeless pumps, and 62% (n=116) used AID systems. Race and insurance were not linked to AID vs non-AID choice, but were associated with CSII initiation. Insurance and race were not associated with selecting an AID over non-AID CSII systems. In glycemic analysis, 183 patients were studied. AID systems showed improved outcomes compared to non-AID systems for the full analysis and sub-analysis of patients outside the honeymoon period.Conclusion: While race and insurance are not associated with the selection of an AID vs non-AID system, they are associated with CSII-starters versus MDI-retainers. As expected, AID systems outperformed non-AID systems in our cohort. Future work will aim to reduce disparities in CSII and AID access for all interested in diabetes technology.
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1568133
Open AccessPatient outcomes after attending pre-pump education class: disparities in initiation and glycemic outcomes
Background: At Children’s of Alabama, all patients with insulin dependent diabetes are considered for continuous subcutaneous insulin infusion therapy (CSII, also known as insulin pump). In some cases, eligibility depends on insurance requirements, including six months of MDI therapy, CSII education, and a six-week glucose log with four daily readings.Objective: Evaluate factors influencing CSII initiation after “Prepump class” and assess glycemic changes in CSII starters.Methods: A retrospective review of pre-pump class attendees from January 2022 to July 2023 was completed. Patients who initiated a CSII prior to January 2024 were identified as “CSII-starters,” and those who remained in multiple daily injections were identified as “MDI-retainers”. Demographic and medical data were compared between these groups. For CSII-starters, type of system and use of automatic insulin delivery (AID) was evaluated. Glycemic outcomes were assessed in those with type 1 diabetes (T1D) with continuous glucose monitor data. A sub-analysis was done for those outside the honeymoon period. Outcomes of AID systems and users of non-AID systems were compared.Results: Of 283 pediatric patients who attended pre-pump class, 187 (66%) started CSII, with a median initiation time of 108 days (interquartile range 76–154). CSII-starters and MDI-retainers differed by race (p=0.0385) and insurance (p=0.0001), but not by sex, language, or age at diagnosis. Initiators were younger (p=0.0150), had shorter diabetes duration (p=0.0001), lower HbA1c (p=0.0020), and higher CGM use (p<0.0001). Among starters, 70% chose tubeless pumps, and 62% (n=116) used AID systems. Race and insurance were not linked to AID vs non-AID choice, but were associated with CSII initiation. Insurance and race were not associated with selecting an AID over non-AID CSII systems. In glycemic analysis, 183 patients were studied. AID systems showed improved outcomes compared to non-AID systems for the full analysis and sub-analysis of patients outside the honeymoon period.Conclusion: While race and insurance are not associated with the selection of an AID vs non-AID system, they are associated with CSII-starters versus MDI-retainers. As expected, AID systems outperformed non-AID systems in our cohort. Future work will aim to reduce disparities in CSII and AID access for all interested in diabetes technology.
- Open Access
- 22 April 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (3) , e70053
Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
Objective: Incidence of type 2 diabetes mellitus (T2DM) and obesity is increasing in children. We aimed to observe the metabolic health effects of glucagon‐like peptide 1 (GLP‐1) receptor agonists in paediatric patients with T2DM in a real‐world setting.Methods: A retrospective chart review of patients aged 0 to 18 years with T2DM who were started on a GLP‐1 receptor agonist between August 2019 and August 2023 and followed for up to 24 months was included in this study.Results: 321 patients were included in the analysis. After 12 months of treatment with a GLP‐1 receptor agonist, haemoglobin A1c (HbA1c) was reduced by −1.04% ± 2.3% (p < 0.001). At 24 months, HbA1c was similar to baseline (8.3% ± 2.5% vs. 7.9% ± 2.5%, p = 0.24). There was a significant (p < 0.05) decrease in the use of metformin, basal insulin, and bolus insulin at one year which was sustained at the two‐year follow‐up for metformin (p = 0.002). Overall, there was no significant change in BMI nor other metabolic parameters while undergoing treatment with a GLP‐1 receptor agonist.Conclusion: Paediatric patients with T2DM using GLP‐1 receptor agonists experienced a significant decrease in HbA1c after 12 months of use, which was not sustained at 24 months. However, patients had a reduction in insulin and metformin use at 12 months. No significant impact was appreciated on BMI or other metabolic variables.
- 22 April 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (3) , e70053
Open AccessEffects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
Objective: Incidence of type 2 diabetes mellitus (T2DM) and obesity is increasing in children. We aimed to observe the metabolic health effects of glucagon‐like peptide 1 (GLP‐1) receptor agonists in paediatric patients with T2DM in a real‐world setting.Methods: A retrospective chart review of patients aged 0 to 18 years with T2DM who were started on a GLP‐1 receptor agonist between August 2019 and August 2023 and followed for up to 24 months was included in this study.Results: 321 patients were included in the analysis. After 12 months of treatment with a GLP‐1 receptor agonist, haemoglobin A1c (HbA1c) was reduced by −1.04% ± 2.3% (p < 0.001). At 24 months, HbA1c was similar to baseline (8.3% ± 2.5% vs. 7.9% ± 2.5%, p = 0.24). There was a significant (p < 0.05) decrease in the use of metformin, basal insulin, and bolus insulin at one year which was sustained at the two‐year follow‐up for metformin (p = 0.002). Overall, there was no significant change in BMI nor other metabolic parameters while undergoing treatment with a GLP‐1 receptor agonist.Conclusion: Paediatric patients with T2DM using GLP‐1 receptor agonists experienced a significant decrease in HbA1c after 12 months of use, which was not sustained at 24 months. However, patients had a reduction in insulin and metformin use at 12 months. No significant impact was appreciated on BMI or other metabolic variables.
- Open Access
- 8 March 2025
- Published by Elsevier in Health Care Transitions
- Vol. 3, 100097
Dynamic assessment of a transition process for patients with diabetes
- 8 March 2025
- Published by Elsevier in Health Care Transitions
- Vol. 3, 100097
Open AccessDynamic assessment of a transition process for patients with diabetes
- Open Access
- 12 September 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (9) , e13602
Continuous glucose monitor metrics and hemoglobin A1c correlation in youth with diabetes: A retrospective analysis of real‐world correlations
- 12 September 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (9) , e13602
Open AccessContinuous glucose monitor metrics and hemoglobin A1c correlation in youth with diabetes: A retrospective analysis of real‐world correlations
- Open Access
- 27 August 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (10)
Association of Patient and Geographic Variables in Pediatric Patients With Prediabetes Becoming Lost to Follow-up
Introduction Prediabetes (PD) is becoming more common, and management is complicated by high rates of loss to follow-up. We evaluated variables associated with lost to follow-up status for pediatric patients with PD referred to endocrinology for evaluation and management. Methods We evaluated new patients referred to Children's of Alabama Endocrinology for PD from March 2017 through March 2021. Variables included patient medical and demographics as well as county-level metrics. Comparisons of patients who returned to clinic and those who were lost to follow-up were assessed by chi-square for categorical variables and Student’s t-test/Wilcoxon rank sum test for continuous normal/skewed variables, respectively. Univariate logistic regression modeling identified risk factors for coming lost to follow-up and odds ratios with 95% confidence intervals were reported with a 2-sided P-value for significance of <.05. Results A total of 524 patients were included in the analysis. Almost one-fourth of patients were lost to follow-up (24.6%). The odds of returning to clinic were higher in patients with the Children's Health Insurance Plan, who were prescribed endocrine medications, who had a concurrent diagnosis of cholesterol disorder, who had referral to the endocrine clinic before COVID-19, and who were offered a telehealth visit. No other assessed variable was significantly associated with the likelihood of returning to clinic. Conclusion Independent of obesity severity, age, sex, race, county-level health, and economic variables, the factor most strongly associated with returning to clinic was having a telemedicine visit scheduled. Our data suggest that offering telemedicine visits may reduce lost to follow-up rates in this patient population.
- 27 August 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (10)
Open AccessAssociation of Patient and Geographic Variables in Pediatric Patients With Prediabetes Becoming Lost to Follow-up
Introduction Prediabetes (PD) is becoming more common, and management is complicated by high rates of loss to follow-up. We evaluated variables associated with lost to follow-up status for pediatric patients with PD referred to endocrinology for evaluation and management. Methods We evaluated new patients referred to Children's of Alabama Endocrinology for PD from March 2017 through March 2021. Variables included patient medical and demographics as well as county-level metrics. Comparisons of patients who returned to clinic and those who were lost to follow-up were assessed by chi-square for categorical variables and Student’s t-test/Wilcoxon rank sum test for continuous normal/skewed variables, respectively. Univariate logistic regression modeling identified risk factors for coming lost to follow-up and odds ratios with 95% confidence intervals were reported with a 2-sided P-value for significance of <.05. Results A total of 524 patients were included in the analysis. Almost one-fourth of patients were lost to follow-up (24.6%). The odds of returning to clinic were higher in patients with the Children's Health Insurance Plan, who were prescribed endocrine medications, who had a concurrent diagnosis of cholesterol disorder, who had referral to the endocrine clinic before COVID-19, and who were offered a telehealth visit. No other assessed variable was significantly associated with the likelihood of returning to clinic. Conclusion Independent of obesity severity, age, sex, race, county-level health, and economic variables, the factor most strongly associated with returning to clinic was having a telemedicine visit scheduled. Our data suggest that offering telemedicine visits may reduce lost to follow-up rates in this patient population.
- Open Access
- 25 October 2023
- Published by Wiley in Pediatric Diabetes
- Vol. 2023, 1-6
Disparities in Glycemic Outcomes Persist in Youth with Type 1 Diabetes and High-Technology Use
Background. Racial disparities are well described in glycemic outcomes in youth with Type 1 diabetes mellites (T1D). Hemoglobin A1c (HbA1c) has some limitations in comparing glycemia across patient groups as there are individual variations in mean glucose and HbA1c. Objective. This study aimed to compare glycemic metrics obtained from (Dexcom G6) continuous glucose monitor (CGM) device with HbA1c levels controlling for race, age, duration of diabetes, race, insurance status, and insulin pump use with glycemic control. Subjects and Methods. Data analyzed included 188 patients, majority non-Hispanic White (NHW) (n = 147, 78.2%) and majority privately insured (n = 147, 78.2%). Half of the patients were using insulin pumps, (n = 94, 50.0%) and approximately half were female. Median age was 16.6 (interquartile range: 14.2–18.2) years old with a median age of diabetes diagnosis at 9.3-years old. Results. Significant differences were observed between NHW and non-Hispanic Black (NHB) patients in terms of HbA1c, 90-day mean glucose, and 90-day time >250 mg/dL (>13.9 mmol/L) (7.6% vs. 9.2%, 181 mg/dL vs. 220 mg/dL, and 16.3% vs. 34.7%, respectively, for all comparisons). Multiple linear regression analysis was performed to predict the influence of age, duration of diabetes, race, insurance status, and insulin administration on glycemic outcomes. Regression analysis revealed significant equations for all glycemic outcomes, demonstrating a strong correlation ( , , and , respectively). However, after controlling for these variables, only race and duration of diabetes remained independently associated with glycemic outcomes, suggesting that these factors strongly influence glycemic control independent of age, sex, insurance, and pump use. Conclusion. Even in a subset of youth with T1D using CGM with high rates of insulin pump use, disparities in glycemic outcomes persist. When evaluating glycemic outcomes, race remained a significant cofactor despite controlling for age, duration of diabetes, sex, insurance status, and insulin administration type. These results add to the existing literature, and demonstrate race remains strong predictor of glycemic outcomes.
- 25 October 2023
- Published by Wiley in Pediatric Diabetes
- Vol. 2023, 1-6
Open AccessDisparities in Glycemic Outcomes Persist in Youth with Type 1 Diabetes and High-Technology Use
Background. Racial disparities are well described in glycemic outcomes in youth with Type 1 diabetes mellites (T1D). Hemoglobin A1c (HbA1c) has some limitations in comparing glycemia across patient groups as there are individual variations in mean glucose and HbA1c. Objective. This study aimed to compare glycemic metrics obtained from (Dexcom G6) continuous glucose monitor (CGM) device with HbA1c levels controlling for race, age, duration of diabetes, race, insurance status, and insulin pump use with glycemic control. Subjects and Methods. Data analyzed included 188 patients, majority non-Hispanic White (NHW) (n = 147, 78.2%) and majority privately insured (n = 147, 78.2%). Half of the patients were using insulin pumps, (n = 94, 50.0%) and approximately half were female. Median age was 16.6 (interquartile range: 14.2–18.2) years old with a median age of diabetes diagnosis at 9.3-years old. Results. Significant differences were observed between NHW and non-Hispanic Black (NHB) patients in terms of HbA1c, 90-day mean glucose, and 90-day time >250 mg/dL (>13.9 mmol/L) (7.6% vs. 9.2%, 181 mg/dL vs. 220 mg/dL, and 16.3% vs. 34.7%, respectively, for all comparisons). Multiple linear regression analysis was performed to predict the influence of age, duration of diabetes, race, insurance status, and insulin administration on glycemic outcomes. Regression analysis revealed significant equations for all glycemic outcomes, demonstrating a strong correlation ( , , and , respectively). However, after controlling for these variables, only race and duration of diabetes remained independently associated with glycemic outcomes, suggesting that these factors strongly influence glycemic control independent of age, sex, insurance, and pump use. Conclusion. Even in a subset of youth with T1D using CGM with high rates of insulin pump use, disparities in glycemic outcomes persist. When evaluating glycemic outcomes, race remained a significant cofactor despite controlling for age, duration of diabetes, sex, insurance status, and insulin administration type. These results add to the existing literature, and demonstrate race remains strong predictor of glycemic outcomes.
- Open Access
- 24 August 2022
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 24 (9) , 619-627
Implicit Racial–Ethnic and Insurance-Mediated Bias to Recommending Diabetes Technology: Insights from T1D Exchange Multicenter Pediatric and Adult Diabetes Provider Cohort
Background: Despite documented benefits of diabetes technology in managing type 1 diabetes, inequities persist in the use of these devices. Provider bias may be a driver of inequities, but the evidence is limited. Therefore, we aimed to examine the role of race/ethnicity and insurance-mediated provider implicit bias in recommending diabetes technology. Method: We recruited 109 adult and pediatric diabetes providers across 7 U.S. endocrinology centers to complete an implicit bias assessment composed of a clinical vignette and ranking exercise. Providers were randomized to receive clinical vignettes with differing insurance and patient names as proxy for Racial–Ethnic identity. Bias was identified if providers: (1) recommended more technology for patients with an English name (Racial–Ethnic bias) or private insurance (insurance bias), or (2) Race/Ethnicity or insurance was ranked high (Racial–Ethnic and insurance bias, respectively) in recommending diabetes technology. Provider characteristics were analyzed using descriptive statistics and multivariate logistic regression. Result: Insurance-mediated implicit bias was common in our cohort ( n = 66, 61%). Providers who were identified to have insurance-mediated bias had greater years in practice (5.3 ± 5.3 years vs. 9.3 ± 9 years, P = 0.006). Racial–Ethnic-mediated implicit bias was also observed in our study ( n = 37, 34%). Compared with those without Racial–Ethnic bias, providers with Racial–Ethnic bias were more likely to state that they could recognize their own implicit bias (89% vs. 61%, P = 0.001). Conclusion: Provider implicit bias to recommend diabetes technology was observed based on insurance and Race/Ethnicity in our pediatric and adult diabetes provider cohort. These data raise the need to address provider implicit bias in diabetes care.
- 24 August 2022
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 24 (9) , 619-627
Open AccessImplicit Racial–Ethnic and Insurance-Mediated Bias to Recommending Diabetes Technology: Insights from T1D Exchange Multicenter Pediatric and Adult Diabetes Provider Cohort
Background: Despite documented benefits of diabetes technology in managing type 1 diabetes, inequities persist in the use of these devices. Provider bias may be a driver of inequities, but the evidence is limited. Therefore, we aimed to examine the role of race/ethnicity and insurance-mediated provider implicit bias in recommending diabetes technology. Method: We recruited 109 adult and pediatric diabetes providers across 7 U.S. endocrinology centers to complete an implicit bias assessment composed of a clinical vignette and ranking exercise. Providers were randomized to receive clinical vignettes with differing insurance and patient names as proxy for Racial–Ethnic identity. Bias was identified if providers: (1) recommended more technology for patients with an English name (Racial–Ethnic bias) or private insurance (insurance bias), or (2) Race/Ethnicity or insurance was ranked high (Racial–Ethnic and insurance bias, respectively) in recommending diabetes technology. Provider characteristics were analyzed using descriptive statistics and multivariate logistic regression. Result: Insurance-mediated implicit bias was common in our cohort ( n = 66, 61%). Providers who were identified to have insurance-mediated bias had greater years in practice (5.3 ± 5.3 years vs. 9.3 ± 9 years, P = 0.006). Racial–Ethnic-mediated implicit bias was also observed in our study ( n = 37, 34%). Compared with those without Racial–Ethnic bias, providers with Racial–Ethnic bias were more likely to state that they could recognize their own implicit bias (89% vs. 61%, P = 0.001). Conclusion: Provider implicit bias to recommend diabetes technology was observed based on insurance and Race/Ethnicity in our pediatric and adult diabetes provider cohort. These data raise the need to address provider implicit bias in diabetes care.
- 29 June 2022
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 24 (7) , 481-491
Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project
Background: : Continuous glucose monitors (CGMs) are a tool that can reduce the burden of self-monitoring of glucose values in children and adults with type 1 diabetes (T1D), are associated with improved glycemic control, and are associated with reduced fear of hypoglycemia. Unfortunately, disparities in access to CGM exist and rates of CGM access in Alabama in 2019 were below national averages. We aimed to increase CGM access and reduce disparities in access by race, insurance status, and high-risk diabetes status. Methods: Stakeholder input identified barriers to CGM access and defined the existing process. Process changes were implemented and studied for effect. Data were collected from the electronic health record to track rates of CGM access in patients aged 2 years and above with T1D for >3 months. Results: For the eligible population, rates of CGM access increased from a baseline of 50% to 82%. Rates for CGM access in patients with high-risk T1D increased from 34% to 85%. Disparity in CGM access for non-Hispanic Whites and non-Hispanic Blacks decreased from 18% to 6%. Disparity in CGM access for privately insured and Medicaid-insured patients decreased from 38% to 12%. Conclusions: Targeted quality improvement projects using stakeholder input can increase access to diabetes technology while reducing disparities. As technology advances, concerted efforts are needed to ensure equitable access to evolving therapies for all patients with T1D.
- 29 June 2022
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 24 (7) , 481-491
Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project
Background: : Continuous glucose monitors (CGMs) are a tool that can reduce the burden of self-monitoring of glucose values in children and adults with type 1 diabetes (T1D), are associated with improved glycemic control, and are associated with reduced fear of hypoglycemia. Unfortunately, disparities in access to CGM exist and rates of CGM access in Alabama in 2019 were below national averages. We aimed to increase CGM access and reduce disparities in access by race, insurance status, and high-risk diabetes status. Methods: Stakeholder input identified barriers to CGM access and defined the existing process. Process changes were implemented and studied for effect. Data were collected from the electronic health record to track rates of CGM access in patients aged 2 years and above with T1D for >3 months. Results: For the eligible population, rates of CGM access increased from a baseline of 50% to 82%. Rates for CGM access in patients with high-risk T1D increased from 34% to 85%. Disparity in CGM access for non-Hispanic Whites and non-Hispanic Blacks decreased from 18% to 6%. Disparity in CGM access for privately insured and Medicaid-insured patients decreased from 38% to 12%. Conclusions: Targeted quality improvement projects using stakeholder input can increase access to diabetes technology while reducing disparities. As technology advances, concerted efforts are needed to ensure equitable access to evolving therapies for all patients with T1D.
- Open Access
- 4 April 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (7) , e2777-e2782
Changes in Type 2 Diabetes Trends in Children and Adolescents During the COVID-19 Pandemic
Context There is concern that the growing incidence of pediatric type 2 diabetes (T2D) may have been further exacerbated by the COVID-19 pandemic. Objective To examine whether trends in new-onset pediatric T2D—inclusive of patients requiring hospitalization and patients managed as outpatients—were impacted during the COVID-19 pandemic, and to compare patient characteristics prior to and during COVID-19. Methods A retrospective single-center medical record review was conducted in a hospital which cares for 90% of Alabama’s pediatric T2D patients. Patients with new-onset T2D referred from March 2017 to March 2021 were included. Counts of patients presenting per month (“monthly rates”) were computed. Linear regression models were estimated for the full sample and stratified by Medicaid and non-Medicaid insurance status. Patient characteristics prior to vs during COVID-19 were compared. Results A total of 642 patients presented with new-onset T2D over this period. Monthly rates were 11.1 ± 3.8 prior to COVID-19 and 19.3 ± 7.8 during COVID-19 (P = .004). Monthly rates for Medicaid patients differed prior to and during COVID-19 (7.9 ± 3.4 vs 15.3 ± 6.6, P = .003) but not for non-Medicaid patients (3.3 ± 1.7 vs 4.0 ± 2.4, P = .33). Regression results showed significant increases in monthly rates during COVID-19 for the full sample (β= 5.93, P < .05) and for Medicaid enrollees (β= 5.42, P < .05) Hospitalization rate, severity of obesity, and hemoglobin A1c remained similar prior to and during COVID-19, though the proportion of male patients increased from 36.8% to 46.1% (P = .021). Conclusions A rise in new-onset T2D was observed among Alabama’s youth during the COVID-19 pandemic, a burden that disproportionately affected Medicaid enrollees and males. Future research should explore the pathways through which the pandemic impacted pediatric T2D.
- 4 April 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (7) , e2777-e2782
Open AccessChanges in Type 2 Diabetes Trends in Children and Adolescents During the COVID-19 Pandemic
Context There is concern that the growing incidence of pediatric type 2 diabetes (T2D) may have been further exacerbated by the COVID-19 pandemic. Objective To examine whether trends in new-onset pediatric T2D—inclusive of patients requiring hospitalization and patients managed as outpatients—were impacted during the COVID-19 pandemic, and to compare patient characteristics prior to and during COVID-19. Methods A retrospective single-center medical record review was conducted in a hospital which cares for 90% of Alabama’s pediatric T2D patients. Patients with new-onset T2D referred from March 2017 to March 2021 were included. Counts of patients presenting per month (“monthly rates”) were computed. Linear regression models were estimated for the full sample and stratified by Medicaid and non-Medicaid insurance status. Patient characteristics prior to vs during COVID-19 were compared. Results A total of 642 patients presented with new-onset T2D over this period. Monthly rates were 11.1 ± 3.8 prior to COVID-19 and 19.3 ± 7.8 during COVID-19 (P = .004). Monthly rates for Medicaid patients differed prior to and during COVID-19 (7.9 ± 3.4 vs 15.3 ± 6.6, P = .003) but not for non-Medicaid patients (3.3 ± 1.7 vs 4.0 ± 2.4, P = .33). Regression results showed significant increases in monthly rates during COVID-19 for the full sample (β= 5.93, P < .05) and for Medicaid enrollees (β= 5.42, P < .05) Hospitalization rate, severity of obesity, and hemoglobin A1c remained similar prior to and during COVID-19, though the proportion of male patients increased from 36.8% to 46.1% (P = .021). Conclusions A rise in new-onset T2D was observed among Alabama’s youth during the COVID-19 pandemic, a burden that disproportionately affected Medicaid enrollees and males. Future research should explore the pathways through which the pandemic impacted pediatric T2D.
- 22 February 2021
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 34 (3) , 333-340
Brain MRIs may be of low value in most children diagnosed with isolated growth hormone deficiency
Objectives: Brain MRIs are considered essential in the evaluation of children diagnosed with growth hormone deficiency (GHD), but there is uncertainty about the appropriate cut-off for diagnosis of GHD and little data about the yield of significant abnormal findings in patients with peak growth hormone (GH) of 7–10 ng/mL. We aimed to assess the frequency of pathogenic MRIs and associated risk factors in relation to peak GH concentrations. Methods: In this retrospective multicenter study, charts of patients diagnosed with GHD who subsequently had a brain MRI were reviewed. MRIs findings were categorized as normal, incidental, of uncertain significance, or pathogenic (pituitary hypoplasia, small stalk and/or ectopic posterior pituitary and tumors). Charges for brain MRIs and sedation were collected. Results: In 499 patients, 68.1% had normal MRIs, 18.2% had incidental findings, 6.6% had uncertain findings, and 7.0% had pathogenic MRIs. Those with peak GH<3 ng/mL had the highest frequency of pathogenic MRIs (23%). Only three of 194 patients (1.5%) with peak GH 7–10 ng/mL had pathogenic MRIs, none of which altered management. Two patients (0.4%) with central hypothyroidism and peak GH<4 ng/mL had craniopharyngioma. Conclusions: Pathogenic MRIs were uncommon in patients diagnosed with GHD except in the group with peak GH<3 ng/mL. There was a high frequency of incidental findings which often resulted in referrals to neurosurgery and repeat MRIs. Given the high cost of brain MRIs, their routine use in patients diagnosed with isolated GHD, especially patients with peak GH of 7–10 ng/mL, should be reconsidered.
- 22 February 2021
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 34 (3) , 333-340
Brain MRIs may be of low value in most children diagnosed with isolated growth hormone deficiency
Objectives: Brain MRIs are considered essential in the evaluation of children diagnosed with growth hormone deficiency (GHD), but there is uncertainty about the appropriate cut-off for diagnosis of GHD and little data about the yield of significant abnormal findings in patients with peak growth hormone (GH) of 7–10 ng/mL. We aimed to assess the frequency of pathogenic MRIs and associated risk factors in relation to peak GH concentrations. Methods: In this retrospective multicenter study, charts of patients diagnosed with GHD who subsequently had a brain MRI were reviewed. MRIs findings were categorized as normal, incidental, of uncertain significance, or pathogenic (pituitary hypoplasia, small stalk and/or ectopic posterior pituitary and tumors). Charges for brain MRIs and sedation were collected. Results: In 499 patients, 68.1% had normal MRIs, 18.2% had incidental findings, 6.6% had uncertain findings, and 7.0% had pathogenic MRIs. Those with peak GH<3 ng/mL had the highest frequency of pathogenic MRIs (23%). Only three of 194 patients (1.5%) with peak GH 7–10 ng/mL had pathogenic MRIs, none of which altered management. Two patients (0.4%) with central hypothyroidism and peak GH<4 ng/mL had craniopharyngioma. Conclusions: Pathogenic MRIs were uncommon in patients diagnosed with GHD except in the group with peak GH<3 ng/mL. There was a high frequency of incidental findings which often resulted in referrals to neurosurgery and repeat MRIs. Given the high cost of brain MRIs, their routine use in patients diagnosed with isolated GHD, especially patients with peak GH of 7–10 ng/mL, should be reconsidered.